Peptide-Enhanced Cell Transduction for Lower Viral Vector Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vector transduction methods for target cells, particularly for cell types like NK cells, are inefficient and costly, necessitating higher Multiplicity Of Infection (MOI) and GMP-compliant vector production, which is expensive and not optimal for therapeutic applications.
Innovation Solution
The use of peptides derived from intermediate filaments, specifically those with amino acid sequences [A/I/L/S/T/V]-[K/R]-[L/I/M/S/T/V/A]-[G/R/A/H/K/S/F]-[L]-[D/E]-[I/N/V/M/K/Q/A/L/G/C]-[E]-[I], either alone or conjugated with amphiphilic polymers, to enhance transduction efficiency by promoting viral vector uptake in target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If higher Multiplicity Of Infection (MOI) is used to improve transduction efficiency, then transduction yield increases, but manufacturing cost increases substantially
Solution Approach 1:
The patent introduces transduction enhancers (chemical compounds or peptides) as intermediary substances that facilitate the interaction between viral vectors and target cells. These enhancers act as mediators that improve transduction efficiency by modifying the cellular environment or enhancing viral entry mechanisms, thereby reducing the quantity of viral vector needed to achieve therapeutic transduction levels.
Solution Approach 2:
The patent employs chemical compounds that alter biochemical parameters within the target cell environment to favor viral transduction. By changing parameters such as membrane permeability, endocytosis efficiency, or viral uncoating conditions, the enhancers enable more effective transduction at lower viral vector doses, thus resolving the contradiction between transduction efficiency and vector quantity required.
2Reliability
If GMP-compliant vector production is implemented to ensure safety, then product quality improves, but manufacturing cost increases
Solution Approach 1:
The patent employs transduction enhancers that can be used in controlled, disposable amounts during the transduction process. These chemical compounds allow for efficient transduction in a single-use manner, reducing the need for expensive, complex, and repeated GMP-compliant vector production cycles. The enhancers enable achieving therapeutic effects with lower vector doses, thereby reducing overall manufacturing costs while maintaining safety through controlled application.
3Productivity
If physical procedures such as spinoculation are used to enhance transduction, then transduction efficiency improves, but procedure complexity and cost increase
Solution Approach 1:
The patent replaces mechanical transduction enhancement methods (such as spinoculation that requires specialized equipment and complex procedures) with chemical transduction enhancers. These chemical compounds simplify the transduction protocol by directly modifying cellular or viral properties to enhance transduction, eliminating the need for complex mechanical devices and procedures while maintaining or improving transduction efficiency.
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3C
AI summary
The invention relates to a method for the transduction of target cells, as well as to products for improving the transduction yield.